Two Sigma Advisers LP Sells 7,980 Shares of Illumina, Inc. (ILMN)

Share on StockTwits

Two Sigma Advisers LP cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 76.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,500 shares of the life sciences company’s stock after selling 7,980 shares during the period. Two Sigma Advisers LP’s holdings in Illumina were worth $750,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC lifted its holdings in Illumina by 61.7% during the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Moody National Bank Trust Division purchased a new stake in Illumina during the 4th quarter worth about $31,000. Virtus ETF Advisers LLC purchased a new stake in Illumina during the 4th quarter worth about $31,000. Oregon Public Employees Retirement Fund lifted its holdings in Illumina by 66,581.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after buying an additional 10,546,495 shares during the last quarter. Finally, Arcadia Investment Management Corp MI purchased a new stake in Illumina during the 4th quarter worth about $39,000. Hedge funds and other institutional investors own 90.46% of the company’s stock.

ILMN opened at $329.50 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.27 and a current ratio of 2.49. Illumina, Inc. has a one year low of $226.62 and a one year high of $372.61. The stock has a market cap of $48.41 billion, a PE ratio of 57.60, a PEG ratio of 2.39 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 EPS for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.04). Illumina had a return on equity of 24.51% and a net margin of 24.79%. The firm had revenue of $867.00 million for the quarter, compared to analyst estimates of $865.33 million. During the same quarter last year, the firm posted $1.44 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, equities research analysts anticipate that Illumina, Inc. will post 6.53 EPS for the current year.

In other news, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $317.01, for a total transaction of $1,046,133.00. Following the sale, the director now owns 331,668 shares in the company, valued at $105,142,072.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert S. Epstein sold 1,000 shares of Illumina stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $314.45, for a total value of $314,450.00. Following the sale, the director now owns 4,256 shares in the company, valued at approximately $1,338,299.20. The disclosure for this sale can be found here. Insiders have sold 34,826 shares of company stock worth $10,604,560 in the last quarter. Insiders own 0.54% of the company’s stock.

A number of brokerages have issued reports on ILMN. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $355.00 price target for the company in a report on Tuesday, April 2nd. OTR Global downgraded Illumina to a “positive” rating in a report on Tuesday, April 2nd. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a report on Tuesday. Bank of America reaffirmed a “buy” rating and set a $355.00 price target on shares of Illumina in a report on Wednesday, January 30th. Finally, Deutsche Bank downgraded Illumina from a “buy” rating to a “hold” rating and set a $296.53 price target for the company. in a report on Friday, January 25th. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Illumina presently has a consensus rating of “Buy” and an average target price of $346.97.

COPYRIGHT VIOLATION WARNING: “Two Sigma Advisers LP Sells 7,980 Shares of Illumina, Inc. (ILMN)” was originally posted by Zolmax and is owned by of Zolmax. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://zolmax.com/investing/two-sigma-advisers-lp-sells-7980-shares-of-illumina-inc-ilmn/3042124.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: Range Trading

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cyberark Software Ltd  Receives Consensus Rating of “Buy” from Analysts
Cyberark Software Ltd Receives Consensus Rating of “Buy” from Analysts
Fennec Pharmaceuticals Inc  Receives Consensus Rating of “Buy” from Brokerages
Fennec Pharmaceuticals Inc Receives Consensus Rating of “Buy” from Brokerages
Douglas Emmett, Inc.  Receives Consensus Recommendation of “Hold” from Analysts
Douglas Emmett, Inc. Receives Consensus Recommendation of “Hold” from Analysts
Landec Co.  Expected to Announce Quarterly Sales of $149.93 Million
Landec Co. Expected to Announce Quarterly Sales of $149.93 Million
CubeSmart  Expected to Post Earnings of $0.41 Per Share
CubeSmart Expected to Post Earnings of $0.41 Per Share
-$0.33 Earnings Per Share Expected for Achieve Life Sciences Inc  This Quarter
-$0.33 Earnings Per Share Expected for Achieve Life Sciences Inc This Quarter


 
© 2006-2019 Zolmax.